Micron to Open New Facility
Micron Technologies (Exton, PA) will officially open the doors to a new facility in Malvern, Pennsylvania, this fall. The
86,000-ft2 site is more than double the size of the company's Exton facility. The new site will house nine processing bays and have
the ability to expand to 18 bays.
Micron Technologies Malvern, Pennsylvania site
The Malvern facility will provide updated processing areas, increased warehouse space, expanded analytical-laboratory testing
facilities, and modern safety and containment technology for highly potent compounds. Facility validation will begin in November
2009, and Micron expects it to be completed by February 2010.
Formatech Donates Manufacturing Services
Under Formatech's (Andover, MA) Fillanthropy Program, the company will donate an aseptic fill and finish manufacturing service
each month for selected therapeutic candidates entering human clinical-trial evaluations.
Formatech is accepting applications for the Fillanthropy Program. Eligible companies must be developing a clinical candidate
delivered as a sterile injectable product. "At Formatech, we envision a world where all companies with promising new drug
therapies have the opportunity to conduct a full clinical development program," said Jeffrey Bernard, Formatech's director
of business development, in a press release.
Catalent Creates New Business Unit
Catalent Pharma Solutions (Somerset, NJ) created a new business unit to help customers bring new pharmaceutical and biologic
products to market. The Development and Clinical Services segment combines Catalent's analytical, science, and regulatory
consulting services with its clinical-supply services business. The company appointed Scott Houlton group president of the
The new segment will support the development and testing of drugs and biologics through scientific, regulatory, and clinical-trial
supply-chain services. Catalent's services extend from drug characterization, to delivering drugs to the investigator site,
through the final submission of regulatory filings.
LabConnect Appoints Chief Operating Officer
LabConnect (Seattle, WA) appointed Frank D. Morrow its chief operating officer. Morrow is a veteran of the central laboratory
business and served as founding executive, president, and chief scientific officer at Quintiles Laboratories Worldwide (Durham,
NC). He helped that company grow to encompass 1000 employees and five central laboratory facilities worldwide over 10 years.
Q&A with Stephen Brown, chief operating officer of Encap Drug Delivery
What is the biggest industry challenge you're now facing?
The biggest challenge facing the pharmaceutical and biotechnology industries is to become more efficient. In essence, the
industry needs to do more with less. This is fairly obvious, given the financial pressures that are being faced by Big Pharma
as major products come off patent and the difficulty that biotechnology companies have in securing funding. Our business is
entirely focused on providing pharmaceutical development and manufacturing services to the pharmaceutical and biotechnology
community, and our challenge is to provide solutions that make our clients' overall operations more efficient.
How do you stay abreast of new developments in the industry?
It is easy to become blinkered and focused on your own backyard. It is really important to keep in touch with what is going
on in the world around you, both in your clients' and competitors' organizations. Having worked for most of my life in pharmaceutical
development, I really enjoy networking and keeping in touch with old work colleagues at Sterling Winthrop (Pittsburgh, PA),
sanofi aventis (Paris), Chiroscience (Cambridge, England), Celltech (Slough, England), and UCB (Brussels). I also think it
is very important to be an active member of professional organizations such as the Academy of Pharmaceutical Sciences and
the American Association of Pharmaceutical Scientists.
Do you see a new industry trend emerging?
I see an increasing trend for pharmaceutical and biotechnology companies to set up strategic relationships with service organizations.
There will be a move away from a client–provider relationship to more of a partnership where the contract service provider
will operate as an extension of the pharmaceutical or biotechnology company. I see this as a great opportunity for the industry
and am sure that the new ways of working that will be required will result in greater speed and efficiency in global pharmaceutical